Impact of Surgical Injury on Haemostatic Tests in Patients Undergoing Total Hip Replacement With Subgroup Analysis of Patients With Neoplasm (I-SIGHT-THR)
Impact of Surgical Injury on Global Haemostatic Tests in Patients Undergoing Total Hip Replacement With Subgroup Analysis of Patients With Bone Neoplasm. A Single-centre Observational Prospective Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Marek Janiak, MD
- Phone Number: 0048225021724
- Email: mjaniak1@wum.edu.pl
Study Locations
-
-
Mazowieckie
-
Warsaw, Mazowieckie, Poland, 02-005
- Recruiting
- I Department of Anesthesiology and Intensive Care Warsaw Medical University
-
Contact:
- Marek Janiak, MD
- Phone Number: 0048225021724
- Email: klinanest1@wum.edu.pl
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adult patients undergoing primary elective total hip replacement
Exclusion Criteria:
- Patients unable to consent to trial
- Active deep and superficial vein thrombosis
- Coagulopathy in initial coagulation screen tests
- Platelet count below 100 thousand
- Patients on antithrombotic medications (except prophylactic low molecular weight heparins and acetylsalicylic acid up to 75 mg per day)
- Preoperative haemoglobin < 10 g/dl
- Female patients who are pregnant or nursing
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients undergoing THR with no known bone neoplasm
Pre- and postoperative blood sampling for ROTEM assessment in THR patients
|
1.8 ml blood sample
Other Names:
|
|
Patients undergoing THR with known bone neoplasm
Pre- and postoperative blood sampling for ROTEM assessment before and after THR in patients with bone neoplasm
|
1.8 ml blood sample
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
INTEM parameters change from preoperative to postoperative values
Time Frame: 30 minutes before and 30 minutes after surgery
|
30 minutes before and 30 minutes after surgery
|
|
EXTEM parameters change from preoperative to postoperative values
Time Frame: 30 minutes before and 30 minutes after surgery
|
30 minutes before and 30 minutes after surgery
|
|
FIBTEM parameter change from preoperative to postoperative values
Time Frame: 30 minutes before and 30 minutes after surgery
|
30 minutes before and 30 minutes after surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total volume of infused fluids
Time Frame: From first fluid on day of surgery to end of surgery, an average of 12 hours
|
Crystalloids, blood products
|
From first fluid on day of surgery to end of surgery, an average of 12 hours
|
|
Pre- and postoperative haemoglobin and haematocrit
Time Frame: From day before surgery to postoperative day 3
|
From day before surgery to postoperative day 3
|
|
|
Intraoperative blood loss
Time Frame: Blood loss as measured during surgery
|
Amount of blood loss in millilitres
|
Blood loss as measured during surgery
|
|
Hip Disability and Osteoarthritis Outcome Score (HOOS)
Time Frame: The day before surgery and at 6 ± 1 months, 12 ± 1 month after surgery
|
Instrument for measuring outcome following surgery with higher scores representing better function.
Score from 0 to 100.
|
The day before surgery and at 6 ± 1 months, 12 ± 1 month after surgery
|
|
The 36-Item Short Form Health Survey (SF-36)
Time Frame: The day before surgery and at 6 ± 1 months, 12 ± 1 month after surgery
|
Health related Quality of Life measure.
Higher score indicates better health state with eight scaled scores each from 0 to 100.
|
The day before surgery and at 6 ± 1 months, 12 ± 1 month after surgery
|
|
Visual Analogue Scale (VAS) score
Time Frame: The day before surgery and at 6 ± 1 months, 12 ± 1 month after surgery
|
The ends of the scale are defined as the extreme limits of the pain.
Orientated from the left (no pain) to the right (worst imaginable pain) measured in millimeters from 0 to 100.
|
The day before surgery and at 6 ± 1 months, 12 ± 1 month after surgery
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate of thrombotic events
Time Frame: up to 12 months after surgery
|
Pulmonary embolism, deep and superficial vein thrombosis
|
up to 12 months after surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jan Pluta, MD, Medical University of Warsaw
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ROTEM-THR
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.